Ocular Infection and Inflammation, Front to Back:
From the ocular surface to the retina, and from basic science to advanced therapeutics

The ISOII Conference will offer the best and latest information on infection and inflammation, from the front of the eye to the back—including in-depth discussions on hot topics in ocular surface disease, drug delivery, nanotechnology, biologics, and more; a 3D surgery symposium; lively panel discussions and debate; and sessions led by key opinion leaders from ophthalmic subspecialties and wide-ranging fields (microbiology, rheumatology, and more).



1. Role of inflammation and infection in ocular surface disease (dry eye disease, blepharitis, allergy)


  • Current and pipeline therapies for inflammation
  • Current and pipeline therapies for infection
  • Role of topical steroids and antiinfectives in dry eye and other ocular surface diseases
  • New technology to treat meibomian glands
  • Blepharitis
  • Allergy
  • Point-of-care diagnostics
  • Neuropathic pain
  • The ocular microbiome

2. Inflammation in glaucoma


  • Local therapy to control wound healing
  • Pathogenesis of glaucoma and role of inflammation
  • Glaucoma surgery and immunomodulatory drugs - 
  • Chronic use of antibiotics after glaucoma surgery

3. Antimicrobial prophylaxis in cataract/ocular surgery


  • Topical antiseptics
  • Topical antibiotics
  • Intracameral antibioics
    - Potential complications with vancomycin and hemorrhagic occlusive retinal vasculitis (HORV)
    - Transzonular/Intravitreal

4. Contact lens-related inflammation and infection


  • Pathogens associated with contact lens-related infections
  • Patient non-compliance
  • Multipurpose disinfectant solution update
  • Management of common ocular surface diseases in the contact lens patient (CLARE, MK, etc)

5. Update on new therapies for infectious and inflammatory uveitis


  • Intravitreal triamsinolone data
  • Ebola, zika, toxoplasmosis
    - Use of sirolimus
  • Immunomodulation
  • Systemic vs intravitreal therapy (MUST study)
  • OCTA and vascular disease in multifocal choroiditis
  • Trends in endophthalmitis and clear corneal surgery

6. Drug delivery to the anterior and posterior segments


  • Topical mitomycin C and iontophoresis
  • Ranibizumab port delivery system, nanoporous silicon
  • Nanochemical aspects of ocular drug delivery
  • Dexamethasone and its timing as adjunct therapy to anti-VEGF therapy for macular disease
  • Brimonidine extended intravitreal delivery system
  • Anterior segment: cyclosporine products

7. Use of topical antiinflammatory therapy and antibiotics for corneal disease


  • Antibiotic use in PK
  • Antiproliferatives
  • Keratoprosthesis
  • Steroids
  • New antibiotics in the pipeline

8. Role of cytokines and inflammation in diabetic retinopathy and macular degeneration


  • Role of steroids vs anti-VEGF
  • Clinical trials of prophylactic anti-VEGF
  • Wide angle imaging
  • New therapeutic targets in PDR and DME
  • Different immunogenetic causes of wet AMD  
  • Brimonidine as neuroprotectant
  • Anti-inflammatory drugs as adjuvant to PDT, anti-VEGF drugs
  • Discussion of different genetic types of AMD
  • Prophylaxis of AMD
  • Long-acting drugs in wet and dry AMD
  • New treatments and clinical trial results in AMD
  • AO angiography

9. Antimicrobial resistance and antibiotic stewardship


  • Current and pipeline antibacterials, antivirals, and antifungals
  • Antimicrobial peptides

10. Imaging in ocular inflammation and infection and related diseases


  • Point-of-care testing
  • Adaptive optics and imaging photoreceptor degeneration
  • Pathogenesis of HIV retinopathy
  • Wide-angle imaging
  • OCT angiography pitfalls 
  • Value of OCTA
  • Multicolor SLO imaging

11. Anterior and posterior ocular inflammation as a consequence of gene and stem cell therapies


  • Intraocular inflammation after gene therapy
  • Intraocular inflammation after stem cell therapy